Association of paediatric mastocytosis with a polymorphism resulting in an amino acid substitution (M541L) in the transmembrane domain of c-KIT

British Journal of Dermatology

Volumn 159, Issue 5, 2008, Pages 1160-1169

  Foster, R ^a,c   Byrnes, E ^a,c   Meldrum, C ^c   Griffith, R ^b,c   Ross, G ^d   Upjohn, E ^d   Braue, A ^d   Scott, R ^a,c   Varigos, G ^d   Ferrao, P ^a,c   Ashman, L K ^a,c  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b UNIVERSITY OF NEWCASTLE   (Australia)

^c JOHN HUNTER HOSPITAL   (Australia)

^d ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

Cutaneous mastocytosis; Proto oncogene protein c Kit; Single nucleotide polymorphism

Indexed keywords

CETIRIZINE; IMATINIB; LEUCINE; METHIONINE; PIMECROLIMUS; STEM CELL FACTOR;

ADOLESCENT; AMINO ACID SUBSTITUTION; ARTICLE; CHILD; CLINICAL ARTICLE; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; DISEASE PREDISPOSITION; DNA POLYMORPHISM; FEMALE; GENE MUTATION; HETEROZYGOSITY; HUMAN; INFANT; MALE; MASTOCYTOSIS; MONOZYGOTIC TWINS; PRIORITY JOURNAL;

ADOLESCENT; AMINO ACID SUBSTITUTION; CELL PROLIFERATION; CHILD; CHILD, PRESCHOOL; DISEASES IN TWINS; EXONS; FEMALE; HUMANS; INFANT; MALE; MASTOCYTOSIS; PIPERAZINES; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; TWINS, MONOZYGOTIC;

EID: 54349098330     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2008.08827.x     Document Type: Article

References (54)

1. Ashman LK. The biology of stem cell factor and its receptor C-kit. Int J Biochem Cell Biol 1999 31 : 1037 51.
2. Lennartsson J, Jelacic T, Linnekin D et al. Normal and oncogenic forms of the receptor tyrosine kinase kit. Stem Cells 2005 23 : 16 43.
3. Irani AM, Nilsson G, Miettinen U et al. Recombinant human stem cell factor stimulates differentiation of mast cells from dispersed human fetal liver cells. Blood 1992 80 : 3009 21.
4. Valent P, Akin C, Sperr WR et al. Mastocytosis: pathology, genetics, and current options for therapy. Leuk Lymphoma 2005 46 : 35 48.
5. Furitsu T, Tsujimura T, Tono T et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest 1993 92 : 1736 44.
6. Tsujimura T, Furitsu T, Morimoto M et al. Ligand-independent activation of c-kit receptor tyrosine kinase in a murine mastocytoma cell line P-815 generated by a point mutation. Blood 1994 83 : 2619 26.
7. Tsujimura T, Furitsu T, Morimoto M et al. Substitution of an aspartic acid results in constitutive activation of c-kit receptor tyrosine kinase in a rat tumor mast cell line RBL-2H3. Int Arch Allergy Immunol 1995 106 : 377 85.
8. Chan PM, Ilangumaran S, La Rose J et al. Autoinhibition of the kit receptor tyrosine kinase by the cytosolic juxtamembrane region. Mol Cell Biol 2003 23 : 3067 78.
9. Hubbard SR. Juxtamembrane autoinhibition in receptor tyrosine kinases. Nat Rev Mol Cell Biol 2004 5 : 464 71.
10. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004 22 : 3813 25.
11. Hirota S, Isozaki K, Moriyama Y et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998 279 : 577 80.
12. Sommer G, Agosti V, Ehlers I et al. Gastrointestinal stromal tumors in a mouse model by targeted mutation of the Kit receptor tyrosine kinase. Proc Natl Acad Sci USA 2003 100 : 6706 11.
13. Moriyama Y, Tsujimura T, Hashimoto K et al. Role of aspartic acid 814 in the function and expression of c-kit receptor tyrosine kinase. J Biol Chem 1996 271 : 3347 50.
14. Tsujimura T, Hashimoto K, Kitayama H et al. Activating mutation in the catalytic domain of c-kit elicits hematopoietic transformation by receptor self-association not at the ligand-induced dimerization site. Blood 1999 93 : 1319 29.
15. Lam LP, Chow RY, Berger SA. A transforming mutation enhances the activity of the c-Kit soluble tyrosine kinase domain. Biochem J 1999 338 : 131 8.
16. Foster R, Griffith R, Ferrao P et al. Molecular basis of the constitutive activity and STI571 resistance of Asp816Val mutant KIT receptor tyrosine kinase. J Mol Graph Model 2004 23 : 139 52.
17. Garcia-Montero AC, Jara-Acevedo M, Teodosio C et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 2006 108 : 2366 72.
18. Nagata H, Worobec AS, Oh CK et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci USA 1995 92 : 10560 4.
19. Ashman LK, Ferrao P, Cole SR et al. Effects of mutant c-kit in early myeloid cells. Leuk Lymphoma 2000 37 : 233 43.
20. Kelly LM, Gilliland DG. Genetics of myeloid leukemias. Annu Rev Genomics Hum Genet 2002 3 : 179 98.
21. Hongyo T, Li T, Syaifudin M et al. Specific c-kit mutations in sinonasal natural killer/T-cell lymphoma in China and Japan. Cancer Res 2000 60 : 2345 7.
22. Kemmer K, Corless CL, Fletcher JA et al. KIT mutations are common in testicular seminomas. Am J Pathol 2004 164 : 305 13.
23. Longley BJ Jr., Metcalfe DD, Tharp M et al. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci USA 1999 96 : 1609 14.
24. Buttner C, Henz BM, Welker P et al. Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behavior. J Invest Dermatol 1998 111 : 1227 31.
25. Middelkamp Hup MA, Heide R, Tank B et al. Comparison of mastocytosis with onset in children and adults. J Eur Acad Dermatol Venereol 2002 16 : 115 20.
26. Rubin BP, Antonescu CR, Scott-Browne JP et al. A knock-in mouse model of gastrointestinal stromal tumor harboring kit K641E. Cancer Res 2005 65 : 6631 9.
27. Shibanuma K, Tong ZB, Vanderhoof VH et al. Investigation of KIT gene mutations in women with 46,XX spontaneous premature ovarian failure. BMC Womens Health 2002 2 : 8.
28. Ferrao P, Gonda TJ, Ashman LK. Expression of constitutively activated human c-Kit in Myb transformed early myeloid cells leads to factor independence, histiocytic differentiation, and tumorigenicity. Blood 1997 90 : 4539 52.
29. Caruana G, Cambareri AC, Ashman LK. Isoforms of c-KIT differ in activation of signalling pathways and transformation of NIH3T3 fibroblasts. Oncogene 1999 18 : 5573 81.
30. Voytyuk O, Lennartsson J, Mogi A et al. Src family kinases are involved in the differential signaling from two splice forms of c-Kit. J Biol Chem 2003 278 : 9159 66.
31. Crosier PS, Ricciardi ST, Hall LR et al. Expression of isoforms of the human receptor tyrosine kinase c-kit in leukemic cell lines and acute myeloid leukemia. Blood 1993 82 : 1151 8.
32. Frost MJ, Ferrao PT, Hughes TP et al. Juxtamembrane mutant V560GKit is more sensitive to imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. Mol Cancer Ther 2002 1 : 1115 24.
33. Ma Y, Zeng S, Metcalfe DD et al. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 2002 99 : 1741 4.
34. Orfao A, Garcia-Montero AC, Sanchez L et al. Recent advances in the understanding of mastocytosis: the role of KIT mutations. Br J Haematol 2007 138 : 12 30.
35. Longley BJ, Tyrrell L, Lu SZ et al. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet 1996 12 : 312 14.
36. Afonja O, Amorosi E, Ashman L et al. Multilineage involvement and erythropoietin-'independent' erythroid progenitor cells in a patient with systemic mastocytosis. Ann Hematol 1998 77 : 183 6.
37. Akin C, Kirshenbaum AS, Semere T et al. Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis. Exp Hematol 2000 28 : 140 7.
38. Yavuz AS, Lipsky PE, Yavuz S et al. Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene. Blood 2002 100 : 661 5.
39. Lawley W, Hird H, Mallinder P et al. Detection of an activating c-kit mutation by real-time PCR in patients with anaphylaxis. Mutat Res 2005 572 : 1 13.
40. Nakagomi N, Hirota S. Juxtamembrane-type c-kit gene mutation found in aggressive systemic mastocytosis induces imatinib-resistant constitutive KIT activation. Lab Invest 2007 87 : 365 71.
41. Akin C, Fumo G, Yavuz AS et al. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 2004 103 : 3222 5.
42. Tang X, Boxer M, Drummond A et al. A germline mutation in KIT in familial diffuse cutaneous mastocytosis. J Med Genet 2004 41 : e88.
43. Zhang LY, Smith ML, Schultheis B et al. A novel K509I mutation of KIT identified in familial mastocytosis -in vitro and in vivo responsiveness to imatinib therapy. Leuk Res 2006 30 : 373 8.
44. Yanagihori H, Oyama N, Nakamura K et al. c-kit mutations in patients with childhood-onset mastocytosis and genotype-phenotype correlation. J Mol Diagn 2005 7 : 252 7.
45. Paquette RL, Hsu NC, Koeffler HP. Analysis of c-kit gene integrity in aplastic anemia. Blood Cells Mol Dis 1996 22 : 159 68.
46. Nagata H, Worobec AS, Metcalfe DD. Identification of a polymorphism in the transmembrane domain of the protooncogene c-kit in healthy subjects. Exp Clin Immunogenet 1996 13 : 210 14.
47. Riva P, Larizza L. A novel potentially diagnostic polymorphism (4894 A/C) in exon 10 of the human c-kit proto-oncogene. Mol Cell Probes 1996 10 : 387 8.
48. Murakami T, Fukai K, Oiso N et al. New KIT mutations in patients with piebaldism. J Dermatol Sci 2004 35 : 29 33.
49. Inokuchi K, Yamaguchi H, Tarusawa M et al. Abnormality of c-kit oncoprotein in certain patients with chronic myelogenous leukemia - potential clinical significance. Leukemia 2002 16 : 170 7.
50. Webster MK, Donoghue DJ. Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia. EMBO J 1996 15 : 520 7.
51. Weiner DB, Liu J, Cohen JA et al. A point mutation in the neu oncogene mimics ligand induction of receptor aggregation. Nature 1989 339 : 230 1.
52. Fleishman SJ, Schlessinger J, Ben-Tal N. A putative molecular-activation switch in the transmembrane domain of erbB2. Proc Natl Acad Sci USA 2002 99 : 15937 40.
53. Casteran N, De Sepulveda P, Beslu N et al. Signal transduction by several KIT juxtamembrane domain mutations. Oncogene 2003 22 : 4710 22.
54. Larizza L, Beghini A. KIT. In : Atlas of Genetics and Cytogenetics in Oncology and Haematology, 1998. Available at: http://atlasgeneticsoncology.org// Genes/KITID127.html (last accessed 17 May 2008).